Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan T Connell

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Blood Advances|March 27, 2024
Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac diseaseLauren E Merz, Duaa AbdelHameid, Dareen M Kanaan, et al.
The Lancet. Haematology|November 5, 2025
Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implicationsOmid Seidizadeh, Ferdows Atiq, Nathan T Connell, et al.
Anti-Cancer Drugs|August 11, 2018
Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization managementEytan Ben-Ami, Maria C Castells, Nathan T Connell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 27, 2022
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experienceEvan C Chen, William Gibson, Paula Temoczko, et al.
American Journal of Hematology|August 4, 2016
Factoring in the missing linkNilay Sethi, Reza Sedighi Manesh, Adam Sperling, et al.
American Journal of Clinical Pathology|December 3, 2020
Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 InfectionOlga Pozdnyakova, Nathan T Connell, Elisabeth M Battinelli, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 16, 2022
von Willebrand disease (VWD) and BATs: How do they connect and why should I care?Leonard A Valentino, Marci L Hardy, Paula James, et al.
JAAD Case Reports|April 8, 2022
Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndromeAmrita Goyal, Damodaran Narayanan, Waihay Wong, et al.
Therapeutic Advances in Hematology|April 8, 2026
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?Robert F Sidonio, Fernando F Corrales-Medina, Jill M Johnsen, et al.
Critical Pathways in Cardiology|May 17, 2019
Andexanet Alfa (Andexxa) Formulary ReviewNahal Beik, Prabashni Reddy, Katelyn W Sylvester, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Blood Advances|March 27, 2024
Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac diseaseLauren E Merz, Duaa AbdelHameid, Dareen M Kanaan, et al.
The Lancet. Haematology|November 5, 2025
Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implicationsOmid Seidizadeh, Ferdows Atiq, Nathan T Connell, et al.
Anti-Cancer Drugs|August 11, 2018
Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization managementEytan Ben-Ami, Maria C Castells, Nathan T Connell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 27, 2022
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experienceEvan C Chen, William Gibson, Paula Temoczko, et al.
American Journal of Hematology|August 4, 2016
Factoring in the missing linkNilay Sethi, Reza Sedighi Manesh, Adam Sperling, et al.
American Journal of Clinical Pathology|December 3, 2020
Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 InfectionOlga Pozdnyakova, Nathan T Connell, Elisabeth M Battinelli, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 16, 2022
von Willebrand disease (VWD) and BATs: How do they connect and why should I care?Leonard A Valentino, Marci L Hardy, Paula James, et al.
JAAD Case Reports|April 8, 2022
Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndromeAmrita Goyal, Damodaran Narayanan, Waihay Wong, et al.
Therapeutic Advances in Hematology|April 8, 2026
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?Robert F Sidonio, Fernando F Corrales-Medina, Jill M Johnsen, et al.
Critical Pathways in Cardiology|May 17, 2019
Andexanet Alfa (Andexxa) Formulary ReviewNahal Beik, Prabashni Reddy, Katelyn W Sylvester, et al.
Pageof 9